VR Logo

BioAtla Inc. (BCAB) download report


Healthcare | Biotechnology & Pharma Research

BioAtla Inc. (BCAB) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

IPO Date: 16-Dec-2020

Co-Founder, CEO & Chairman: Dr. Jay M. Short Ph.D.

Pres & Director: Mr. Scott Andrew Smith

Listing: NASDAQ: BCAB

Country: United States

Headquarters: San Diego, CA

Website: https://www.bioatla.com

Key Facts

Market cap: $132.82 Mln

Revenue (TTM): $0.50 Mln

Earnings (TTM): $-100.96 Mln

Cash: $219.43 Mln

Total Debt: $5.04 Mln

Insider's Holding: 16.34%

Liquidity: Low

52 Week range: $2.03 - 47.86

Shares outstanding: 35,921,900

Stock Performance

Time Period BioAtla (BCAB) S&P BSE Sensex* S&P Small-Cap 600*
YTD-84.41-8.71-17.14
1 month32.47-3.11-4.85
3 months-31.54-7.29-12.74
1 Year-92.840.48-16.37
3 Years--10.347.97
5 Years--11.436.33
10 Years--12.1010.54
As on 27-Jun-2022 *As on 28-Jun-2022
Year BioAtla (BCAB) S&P Small-Cap 600 S&P BSE Sensex
2021-42.2825.2721.99